



Pioneering science delivers vital medicines™

Amgen 2015 Environmental Sustainability Report Highlights



MEMBER OF
**Dow Jones
Sustainability Indices**
In Collaboration with RobecoSAM

Leadership Message



Robert A. Bradway

Highlighted by our launch of six innovative products, 2015 was a year in which Amgen advanced our strategy for long-term growth. We delivered new and existing medicines for patients in more countries than ever before, executing our ambitious plans even as we made transformational changes to make us stronger and more competitive. As Amgen evolves, we remain committed to being a responsible company. We strive to extend the positive impact our medicines make around the world to our work in the communities in which we operate. We commit significant time, energy, and resources to efforts that make us a better global citizen.

Environmental sustainability is one aspect of Amgen's responsible approach. As a biology-focused company, we have a deep appreciation for the natural environment. We continuously improve operations in a variety of ways to improve our environmental impact. We are making progress toward licensure of our pioneering Next-Generation Biomanufacturing plant in Singapore, which will considerably curb water use, carbon emissions, and the generation of solid waste. In response to drought, we accelerated our already-substantial water conservation efforts at sites in California and Puerto Rico. We have achieved large reductions in carbon emissions from our overall business primarily by making systems more efficient and using less energy. We have evaluated renewable and alternative energy technology options at every major Amgen site and have included renewable and alternative energy projects in our long range plan.

We are proud to be recognized externally for our sustainability performance. In 2015, Amgen earned placement on the Dow Jones Sustainability World Index for a second year and was named to the North America Index for a third year. Amgen placed significantly higher in both the US and Global listings in the Newsweek 2015 Green Rankings compared to previous years.

We have launched a Responsibility section on Amgen.com as part of our broader commitment to communicating our non-financial performance. In addition to this environmental sustainability report, the section contains information on the Amgen Foundation, our Access to Medicine program, corporate giving initiatives, and the health and safety of our staff.

Just as I value how our staff are motivated by the opportunity to make the world a better place, I appreciate that our peers and the public take time to review and assess Amgen's performance. I invite you to share your thoughts about Amgen's progress with environmental sustainability through the feedback link on this report website.

A handwritten signature in black ink that reads "Robert A. Bradway". The signature is fluid and cursive.

Robert A. Bradway
Chairman and Chief Executive Officer

This brochure, a supplement to Amgen's 2015 Environmental Sustainability Report found at environment.amgen.com, highlights how the company is making steady progress to deliver on the goals of our 2020 Environmental Sustainability Plan and Targets. We've proven that sustainable operations are a wise investment, improving efficiency and creating value.


Our Targets



The overall aim of our 2020 targets is to protect the environment, improve efficiency, and increase stakeholder value. Our targets are designed to track our progress through deliberate efforts—without influence from growth or contraction in our business. We created a portfolio of projects and initiatives that we specifically execute to bring results in our target areas. We track the performance of these projects and initiatives against a 2012 baseline, counting results of projects and initiatives confirmed through a formal measurement process.

2020 Target

Progress Through 2015



*Currently showing progress for US sales fleet. Baseline is being established for sales fleet outside the US, which will be integrated into target.

We are integrating environmental sustainability practices throughout our company's operations—from research and manufacturing practices to the design and construction of facilities. A mix of facility and process optimization practices combined with carefully selected technology advances creates results.

Sustainability in Action



Driving Sustainable Practices Throughout the Value Chain

Amgen's 2020 plan for environmental sustainability is focused on driving sustainable practices in the areas of research, development, and manufacturing; transportation and distribution; commercial operations; sourcing; and products and packaging. By integrating sustainable practices during the design process, we are achieving further efficiencies in our business while continuing to reduce our impact on the environment.

Conserving a Precious Resource

Water is vital to life and is a key ingredient in Amgen medicines. Our staff members strive to conserve water in strategic ways that support our business while recognizing our responsibilities to the communities in which we operate. Our two largest sites are situated in locations—California and Puerto Rico—that experienced extreme drought conditions in 2015. We moved quickly to assess and implement short- and long-term strategies to enhance existing water conservation programs at all sites in these locations. Amgen as a whole was able to conserve 106,000 cubic meters of water in 2015.

The Environmental Benefits of Manufacturing Advances

Amgen has pioneered Next-Generation Biomanufacturing technologies that allow for greater productivity in a footprint

that is significantly smaller than a conventional facility. We plan to use this approach for the first time commercially following licensure at our new manufacturing center in Singapore. Compared to a large facility, a Next-Generation plant can provide major reductions in carbon emissions, energy consumption, water use, and solid waste. Advanced technologies for drug product manufacturing and process improvements in conventional biomanufacturing also create conservation gains in addition to improving efficiency and saving financial resources in our business.

Seizing the Opportunity to Expand Recycling

Biomanufacturing involves the use of many different materials that can be challenging to recycle depending on the local waste management services available. At our manufacturing facility in Rhode Island, staff have waited patiently for the right opportunity to recycle non-regulated manufacturing waste items such as used filters, bio-bags, wave-bags, tubing, and nitrile gloves rather than send them to the landfill. When Amgen's vendor for waste management grew their service to take previously un-recyclable items, process them, and make them into useful items like park benches and curb material, Amgen signed on to send these items to a more environmentally friendly fate. These efforts diverted 90 metric tons of waste from the landfill for recycling.

The success of our environmental sustainability plan depends on the creativity and resourcefulness of our staff, who demonstrate their commitment to the environment both at work and in their communities.



Amgen staff approach opportunities to make environmental improvements with the same enthusiasm and rigor they apply to scientific challenges. Staff-supported improvements in technology and processes have created significant conservation benefits, saved financial resources, and earned many awards over the years. Amgen maintains a yearly Environmental Champions program, which honors numerous staff from around the company for their green actions.

Reaching Out in the Community

Amgen staff are avid volunteers, contributing to a number of environmentally beneficial events throughout the year. Various Amgen sites participate annually in the International Coastal Cleanup, a global volunteering opportunity in which participants clear waterways and beaches of trash while collecting data that support the Ocean Conservancy in its goal of trash-free seas. Other environmental volunteering events in which staff participate include Clean Up Australia Day and a work party at Kendall Square in Massachusetts. The National Parks Service and Ventura County honored Amgen volunteers for their commitment to the community and the environment in 2015.

The Amgen Foundation is deeply committed to fostering the next generation of scientific innovators, including our support of important initiatives that advance environmental education in our local communities, such as NatureBridge school programs at the Golden Gate National Park campus and in the Santa Monica Mountains.

Sustainable Commuting

Amgen supports carpools, vanpools, public transportation vouchers, bicycle commuting, and electric car charging where possible. We tailor our alternative transportation programs to the resources available in the communities where Amgen operates facilities.

Education for the Environment

Amgen celebrated Earth Day at most of its US-based locations in 2015. Events encouraged staff to develop environmentally friendly habits both at work and at home in the areas of recycling, composting, waste reduction, energy efficiency, and alternative commuting. Water conservation was of special importance during drought conditions in 2015, and Earth Day events focused on things that staff can do at home and at work to conserve water. Various Amgen sites promoted waste reduction and recycling strategies in support of America Recycles Day.

Performance




Conserving Resources

Conserving energy allows Amgen to retain more financial resources for our core business of discovering, developing, manufacturing, and delivering innovative human therapeutics. Amgen has a comprehensive carbon reduction strategy that focuses on eliminating energy use, increasing energy efficiency, and increasing the proportion of renewable and alternative energy used. We complete utilities projects that provide substantial returns for both energy savings and carbon reduction across our network of facilities around the world. Two solar projects are currently scheduled for implementation. We have realized millions in cost savings and reduced carbon emissions by 97,500 metric tons, or 23 percent, from 2008 through 2015 by implementing energy conservation and carbon reduction projects.

We are making progress towards our sales fleet carbon reduction target, raising the minimum fuel efficiency standard for vehicles year by year. We continue to expand the range of fuel-efficient vehicle choices available for mobile staff—and to rotate out less fuel-efficient vehicles.

Carbon


2007–2015 Carbon Emissions and Carbon Emissions Avoided* Through Conservation Efforts (1,000 MT)



*Value represents year-over-year, cumulative and continuing avoidance.

Energy


2007–2015 Energy Use and Energy Use Avoided* Through Conservation Efforts (1,000 GJ)



*Value represents year-over-year, cumulative, and continuing avoidance.

Fuel Efficiency

2007–2015 US Fleet Fuel Use and Fuel Use Avoided Through Conservation (per 1,000 Gal)*




*Value represents continued avoidance based on fleet efficiency improvements




Waste

The Waste Hierarchy as a Model for Our Waste-Reduction Goals




2007–2015 Routine Waste Categorized by Waste Hierarchy (Metric Tons)



Water

2007–2015 Water Intake and Intake Avoided* Through Conservation Efforts (1,000 CM)



*Value represents year-over-year, cumulative and continuing avoidance.

Reducing Waste; Saving Water

Amgen has improved the rate of recycling from 35 percent to 52 percent from 2007 through 2015. To build on the success of existing programs and uncover new ways to stop waste at the source, we continue to analyze waste audits conducted at our largest sites. We use data from these audits to shape initiatives for recycling and waste reduction.

Amgen continues to assess water use and employ data-driven approaches to identify new opportunities to capture water savings, especially at our largest sites located in drought-prone geographies. We integrate water-saving practices and technologies such as smart irrigation systems, low-water landscaping, and waterless urinals. A key component of Amgen's water conservation program is a wastewater treatment plant at our manufacturing site in Puerto Rico that has enabled an average of 70 percent of the treated wastewater to be recycled on-site each year. Energy conservation projects often provide water conservation benefits.

This report contains Standard Disclosures from the Global Reporting Initiative (GRI) Sustainability Reporting Guidelines. The GRI guidelines offer a useful framework to help companies standardize their sustainability reporting.

The scope of the environmental data in our report includes 20 manufacturing, research and development, and distribution facilities in North America, South America, Europe, and Eurasia. These facilities represent approximately 94 percent of our operations, based on the square footage of our facilities. The remaining square footage primarily includes administrative offices. Recently acquired facilities are outside the scope of this report.

Our 2015 environmental data for this report has undergone limited assurance by Bureau Veritas.

The index summarizes Amgen's disclosures in relation to the GRI G4 indicators.

Strategy and Analysis

Number	Disclosure	Reported	Response
G4-1	CEO statement: relevance of sustainability to the company	●	environment.amgen.com (<i>Leadership Message</i>)

Organizational Profile

Number	Disclosure	Reported	Response
G4-3	Name of the organization	●	Amgen
G4-4	Primary brands, products, and services	●	www.amgen.com (<i>Product websites</i>)
G4-5	Location of headquarters	●	Thousand Oaks, CA
G4-6	Number of countries of operation	●	www.amgen.com (<i>Amgen Fact Sheet</i>)
G4-7	Nature of ownership and legal form	●	www.amgen.com (<i>Amgen Fact Sheet</i>)
G4-8	Markets served	●	www.amgen.com (<i>Amgen Fact Sheet</i>)
G4-9	Scale of organization (number of staff, number of operations, net sales, debt/equity, quantity of products provided)	◐	www.amgen.com (<i>Amgen Fact Sheet</i>)
G4-10	Staff information: number, region, gender, etc.	◐	www.amgen.com (<i>Amgen Fact Sheet</i>)
G4-13	Any changes during reporting period	●	Amgen closed its facilities in Washington and Colorado at the end of 2015.

Identified Material Aspects and Boundaries

Number	Disclosure	Reported	Response
G4-17	Entities covered by the report	●	<p>Amgen facilities within the scope of this report are as follows:</p> <p>United States: : Thousand Oaks, California; Cambridge, Massachusetts; Woburn, Massachusetts; Greenwich, Rhode Island; Louisville, Kentucky; South San Francisco, California; Boulder and Longmont, Colorado; Juncos, Puerto Rico; Seattle and Bothell, Washington; Field Sales US Fleet</p> <p>Canada: Burnaby, British Columbia</p> <p>Europe: Breda, Netherlands; Uxbridge, Abingdon, and Cambridge, United Kingdom; Dun Laoghaire, Ireland</p> <p>Brazil: São Paulo</p> <p>Turkey: Yenibosna and Sekerpinar</p>

Identified Material Aspects and Boundaries (continued)

Number	Disclosure	Reported	Response
G4-18	Process for defining report content and determining boundaries for aspects	Partial	environment.amgen.com (Amgen's Environmental Sustainability Plan) environment.amgen.com (Stakeholder Engagement)
G4-19	List all material aspects	Partial	environment.amgen.com (Amgen's Environmental Sustainability Plan)
G4-22	Effects of any restatements from information provided in previous reports	Reported	No restatements
G4-23	Significant changes from previous reports in scope or aspect boundaries	Reported	Amgen closed its facilities in Washington and Colorado at the end of 2015. Data from our facilities in Brazil and Turkey are now included in the 2015 report.

Stakeholder Engagement

Number	Disclosure	Reported	Response
G4-24	Stakeholder groups engaged by the organization	Partial	environment.amgen.com (Stakeholder Engagement)

Report Profile

Number	Disclosure	Reported	Response
G4-28	Reporting period	Reported	January 1, 2015, to December 31, 2015
G4-29	Date of most previous report	Reported	May 2015
G4-30	Reporting cycle	Reported	Annual
G4-31	Contact for questions regarding report	Reported	esfeedback@amgen.com
G4-32	GRI content index	Reported	environment.amgen.com (GRI Index)
G4-33	Scope and basis of external assurance	Reported	environment.amgen.com (Assurance)

Governance

Number	Disclosure	Reported	Response
G4-34	Governance structure of the organization	Reported	environment.amgen.com (Governance)

Ethics and Integrity

Number	Disclosure	Reported	Response
G4-56	Organization's values, principles, standards and norms of behavior	Reported	www.amgen.com (Mission and Values)

Economic

Number	Disclosure	Reported	Response
G4-EC1	Direct economic value generated and distributed	Yes	www.amgen.com (2015 Annual Report and Financial Summary)
G4-EC2	Financial implications and other risks and opportunities for the organization's activities due to climate change	Yes	We're actively working to conserve energy and reduce greenhouse gas emissions that result from our operations. We have also considered potential risks to our business associated with climate change such as extreme weather events and increasing regulation. Financial impact is considered as part of our risk management processes. Having plans in place to mitigate these risks increases the overall sustainability of the business.
G4-EC8	Significant indirect economic impacts, including the extent of impacts	Partial	www.amgen.com (Amgen Foundation)

Environmental

Number	Disclosure	Reported	Response
G4-EN3	Energy consumption within the organization	●	environment.amgen.com (Energy Performance)
G4-EN4	Energy consumption outside the organization	●	environment.amgen.com (Energy Performance)
G4-EN6	Reduction of energy consumption	●	environment.amgen.com (Energy Performance)
G4-EN8	Total water withdrawal by source	●	environment.amgen.com (Water Approach)
G4-EN10	Percentage and total volume of water recycled and reused	●	environment.amgen.com (Water Approach)
G4-EN15	Direct Greenhouse Gas emissions (Scope 1)	●	environment.amgen.com (Carbon Performance)
G4-EN16	Energy Indirect Greenhouse Gas Emissions (Scope 2)	●	environment.amgen.com (Carbon Performance)
G4-EN17	Other Indirect Greenhouse Gas Emissions (Scope 3)	◐	environment.amgen.com (Summary of Data)
G4-EN19	Reduction of Greenhouse Gas Emissions	●	environment.amgen.com (Carbon Performance)
G4-EN23	Total weight of waste by type and disposal method	●	environment.amgen.com (Summary of Data)
G4-EN24	Total number and volume of significant spills	●	There were no significant spills in 2015.
G4-EN27	Extent of impact mitigation of environmental impacts of products and services	◐	environment.amgen.com (Products and Packaging)
G4-EN28	Percentage of products sold and their packaging materials that are reclaimed by category	◐	environment.amgen.com (Products and Packaging)
G4-EN29	Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations	●	None
G4-EN30	Significant environmental impacts of transporting products and other goods and materials for the organization's operations, and transporting members of the workforce	◐	environment.amgen.com (Summary of Data)

Society Performance Indicators

Number	Disclosure	Reported	Response
G4-LA6	Type of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities, by region and by gender	◐	www.amgen.com (Safety and Wellness)
G4-LA10	Programs for skills management and lifelong learning that support the continued employability of employees and assist them in managing career endings	◐	www.amgen.com (Training and Development)
G4-LA12	Composition of governance bodies and breakdown of employees per employee category according to gender, age group, minority group membership, and other indications of diversity	◐	www.amgen.com (Corporate Governance)
G4-S04	Communication and training on anti-corruption policies and procedures	●	www.amgen.com (Corporate Compliance Policies)
G4-S06	Total value of political contributions by country and recipient/beneficiary	◐	www.amgen.com (Political Contributions)
G4-PR1	Percentage of significant product and service categories for which health and safety impacts are assessed for improvement	◐	www.amgen.com (Patient Safety)

Energy (a)

Type	Unit	2007	2011	2012	2013	2014	2015
Total Combustion On-site (Direct) (d)	1,000 GJ	2,151	1,897	1,790	1,828	1,744	1,828
Natural Gas	1,000 GJ	1,848	1,462	1,390	1,400	1,322	1,371
Diesel	1,000 GJ	303	425	390	416	411	448
Propane	1,000 GJ	0	10	10	11	11	10
Total Purchased Energy (Indirect) (e)	1,000 GJ	2,190	2,006	2,059	1,990	1,962	1,983
Fossil Fuel	1,000 GJ	1,541	1,497	1,545	1,435	1,418	1,419
Hydro	1,000 GJ	287	196	191	210	200	217
Nuclear	1,000 GJ	240	194	195	185	185	178
Nonspecified Renewables	1,000 GJ	106	107	114	152	144	156
Nonspecified	1,000 GJ	16	13	13	8	14	13
Total Energy	1,000 GJ	4,341	3,903	3,849	3,817	3,706	3,812
Total Energy Normalized to Net Sales	1,000 GJ/\$B net sales	303	255	231	210	192	182
Confirmed Results of Energy Reduction Projects (b,c)	1,000 GJ	-	718	919	106	131	175

Carbon (a)

Type	Unit	2007	2011	2012	2013	2014	2015
Total Carbon Combustion On-site (Scope 1) (f)	1,000 MT CO ₂ Eq	126	104	98	101	96	103
Natural Gas	1,000 MT CO ₂ Eq	104	74	70	71	67	71
Diesel	1,000 MT CO ₂ Eq	22	30	27	29	29	32
Propane	1,000 MT CO ₂ Eq	-	0.60	0.63	1	1	1
Total Carbon Purchased Energy (Scope 2) (g)	1,000 MT CO ₂ Eq	290	277	287	263	258	266
Electricity	1,000 MT CO ₂ Eq	284	273	283	259	254	263
Steam	1,000 MT CO ₂ Eq	6	4	4	4	4	3
Total Carbon from Energy	1,000 MT CO ₂ Eq	416	381	385	363	354	369
Total Carbon Normalized to Net Sales	1,000 MT CO ₂ Eq/ \$B net sales	29.1	24.9	23.1	20	18	18
Total Carbon Normalized to Total Energy	MTCO ₂ Eq/GJ	0.095	0.098	0.100	0.095	0.10	0.097
Confirmed Results of CO ₂ Reduction Projects (b,c)	1,000 MT CO ₂	0	63	84	8	10	13.5

Other Carbon ^(h)

Type	Unit	2007	2011	2012	2013	2014	2015
Carbon US Sales Fleet (Scope 1)	1,000 MT CO ₂ Eq	13	16	15	16	13	13
Carbon US Sales Fleet Emissions Avoided (Scope 1) ^(o)	1,000 MT CO ₂ Eq	0	3	4	1	2	2.3
Carbon Executive Air Fleet (Scope 1)	1,000 MT CO ₂ Eq	5	7	6	5	5	6
Carbon from Fugitive Refrigerant Emissions (Scope 1)	MT CO ₂ Eq	-	-	-	4,231	5,499	3,958
Carbon Business Travel - Commercial (Scope 3) ^(i,j)	1,000 MT CO ₂ Eq	-	50	65	67	65	74
Carbon from Amgen Materials Transportation (Scope 3) ^(i,j)	1,000 MT CO ₂ Eq	-	-	25	27	25	29

Water ^(a)

Type	Unit	2007	2011	2012	2013	2014	2015
Total Water Withdrawal ^(k,c)	1,000 CM	3,286	2,577	2,720	2,725	2,487	2,520
Municipal	1,000 CM	3,249	2,560	2,707	2,712	2,482	2,453
Other - (Reservoir) Trucked In	1,000 CM	8	-	-	-	-	-
Ground	1,000 CM	29	17	13	13	5	68
Total Water Withdrawal Normalized to Net Sales	1,000 CM/\$B net sales	230	169	163	150	129	120
Water Fate	1,000 CM	-	2,584	2,720	2,739	2,487	2,512
Consumed Into Products	1,000 CM	-	20	21	21	28	71
Lost to Evaporation	1,000 CM	-	633	713	684	657	736
Discharged to Treatment	1,000 CM	-	1,663	1,662	1,758	1,551	1,449
Discharged Directly to Environment	1,000 CM	-	267	324	276	250	256
Recycled	1,000 CM	-	533	535	655	525	759
Percentage of Water Recycled per Total Water Withdrawal	%	-	21	20	24	21	30%
Confirmed Results of Water Reduction Projects ^(b)	1,000 CM	-	673	686	19	36	142

Waste (a, c)

Type	Unit	2007	2011	2012	2013	2014	2015
Diversion from Landfill Rate (l)	%	38	59	59	-	-	-
Recycling Rate (l)	%	34.9	53.9	52.8	51.3	50.4	52.1
Total Routine Waste	MT	10,146	9,645	9,018	8,780	8,929	10,054
Hazardous Waste	MT	1,343	1,116	1,180	1,157	1,113	1,455
Recycled	MT	251	235	245	105	84	190
Incinerated for Energy Recovery	MT	375	284	347	402	387	447
Incinerated Not for Energy Recovery	MT	523	424	422	468	473	683
Landfilled	MT	118	153	126	147	132	102
Treated (m)	MT	76	20	40	36	38	33
Nonhazardous Waste	MT	8,803	8,529	7,838	7,623	7,816	8,599
Composted	MT	260	485	583	532	628	947
Reused	MT	32	60	44	274	178	153
Recycled	MT	2,999	4,418	3,890	3,583	3,610	3,945
Incinerated for Energy Recovery	MT	432	397	576	604	605	700
Incinerated Not for Energy Recovery	MT	194	176	79	48	88	259
Landfilled	MT	4,885	2,985	2,662	2,530	2,661	2,543
Treated (m)	MT	-	8	4	52	47	52
Total Routine Waste Normalized to Net Sales	MT/\$B net sales	709	631	542	483	462	480
Total Nonroutine Waste (n)	MT	31,415	12,458	16,902	8,452	3,722	2,253
Confirmed Results of Routine Waste Reduction Projects (b)	MT	-	875	1,094	320	441	688

Fleet

Type	Unit	2007	2011	2012	2013	2014	2015
US Sales Fleet Fuel Efficiency	MPG-US	19	23	23	25	26	27
US Sales Fleet Fuel Use Avoided (o)	1,000 GL	-	363	427	104	289	498
US Sales Fleet Fuel Use	1,000 GL	1,498	1,784	1,739	1,738	1,381	1,414

Compliance (a)

Type	Unit	2007	2011	2012	2013	2014	2015
Environmental Notices of Violation (NOVs) (w)	# NOV	8	2	2	2	6	1

General

- (a) Amgen has included data from 20 facilities covering energy and carbon, water, and waste. The facilities represent approximately 94 percent of Amgen's worldwide facility space based on total square feet. Included facilities are in Thousand Oaks, California, US; Greenwich, Rhode Island, US; Boulder and Longmont, Colorado, US; Seattle and Bothell, Washington, US; Juncos, Puerto Rico, US; Louisville, Kentucky, US; South San Francisco, California, US; Cambridge and Woburn, Massachusetts, US; Burnaby, Canada; Breda, Netherlands; Dun Laoghaire, Ireland; Uxbridge, Abingdon, and Cambridge, United Kingdom; Sao Paulo, Brazil; and Yenibosna and Sekerpinar, Turkey. This includes leased buildings where we have operational control over building infrastructure, including utilities. In 2011, Amgen acquired a facility in São Paulo. In 2012, Amgen acquired four companies: Micromet, KAI Pharmaceuticals, deCODE genetics, and Mustafa Nevzat Pharmaceuticals. In 2013 Amgen acquired Onyx Pharmaceuticals. No data will be included for our Micromet, KAI Pharmaceuticals, deCODE genetics, or Onyx Pharmaceuticals in this report, as we are still working through the integration process for these facilities.
- (b) Measurement and verification of conservation and reduction projects for energy and carbon, water, and waste are based on adaptation of the International Performance Measurement and Verification Protocol (IPMVP), Concepts and Options for Determining Energy and Water Savings Volume 1, EVO 10000-1.2007, April 2007. Project measurements are conducted using reasonable means, including direct measurements and scientific estimations as appropriate. Values for conservation and reduction projects represent year-over-year, cumulative and continuing avoidance based on a 2007 baseline, then rebaselined in 2012 to match the next generation 2020 Target design. Results from conservation and reduction projects from sites in Brazil and Turkey are not included in the 2015 report.
- (c) Immaterial changes to 2007–15 data may have occurred due to refinements in calculations. All changes have been confirmed through a documented change control process.

Energy

- (d) Direct energy use results from the operation of equipment that is owned or controlled by Amgen at the facilities listed in note (a). Data on the use of natural gas, propane, and diesel in boilers, furnaces, and HVAC are recorded from utility bills or purchase records. Data on the use of diesel in emergency generators are recorded from purchase records or meter readings and, in some cases, estimated from run-hours. Utility bills recorded in units of volume are converted to energy by using the Global Reporting Initiative Version 3.1, EN3 table, to convert volumes of primary sources (natural gas, diesel), or from specific fuel analysis data (diesel used in Juncos, Puerto Rico), and the US Energy Information Administration/Annual Energy Review Table A1 (propane). Energy from emergency generators recorded as run-hours is estimated using the manufacturer's specified fuel-feed rate for each generator.
- (e) Indirect energy use results from purchased energy in the forms of electricity and steam at the Amgen facilities listed in note (a). Data on the use of electricity and steam are recorded from utility bills. Utility bills for purchased steam that are recorded in units of mass (i.e., 'lb steam') are converted to energy by using the latent heat of evaporation from the saturated steam tables, then dividing by the efficiency of the supplier's steam generator.

Carbon

- (f) Scope 1 carbon emissions result from direct energy sources defined in note (d). Additional Scope 1 Carbon emissions from our US sales fleet, executive air fleet, and fugitive emissions from chillers, coolers, and HVAC are found in the Other Carbon category in this data summary. Carbon data from natural gas sources are calculated using regional specific emission factors from US EPA Rule Part 98A Table C-3 (US weighted average) for all US sites; from the Ireland UFCCC for Amgen's facility in Dun Laoghaire, Ireland; from U.K. Defra/DECC's 110819 Guidelines for Amgen's facilities in the United Kingdom (Uxbridge, Abingdon, and Cambridge); from the NL Agency standard CO₂ emission factors for Amgen's facility in the Netherlands (Breda); and from the Methodology for Reporting 2013 Ministry of Environment Victoria, BC, 2013, for Amgen's facility in Burnaby, Canada. Carbon emissions data from propane and diesel fuel sources (except Amgen's facility in Juncos, Puerto Rico) are calculated using the Greenhouse Gas Protocol Cross-Sector Tools-Stationary Combustion-V.1.0 (August 2012). Carbon from diesel use in Amgen's Juncos, Puerto Rico, facility are calculated using specific fuel analysis information and from US EPA Rule Part 98A Table C-1. Carbon data from direct energy sources prior to 2011 were calculated using emission factors from the Greenhouse Gas Protocol Cross-Sector Tools-Stationary Combustion-V.1.0 (Jul 2009). Scope 1 emissions that are not included in this data summary include process-related emissions from cell respiration (carbon as a by-product) and pH adjustments (CO₂ injection). Analysis of these sources in 2013 showed that cell respiration and emissions from pH adjustments are negligible (less than 0.1 percent of our total carbon emissions).
- (g) Scope 2 carbon emissions result from indirect energy sources defined in note (e). Carbon data from purchased electricity are calculated using emission factors from US EPA eGRID 2012 for all US locations except Amgen's facility in Puerto Rico, which has been determined using EPA GHG Report YE 2012 for Power Suppliers in Puerto Rico; from the Greenhouse Gas Division, Environment Canada (2006 data)-V.1.0 (April 2009) for Amgen's facility in Burnaby, Canada; and from specific utility annual providers' reports for Amgen facilities in the United Kingdom (Uxbridge, Abingdon, and Cambridge), the Netherlands (Breda), and Dun Laoghaire, Ireland. Carbon data from purchased steam are calculated using the Emission Factor for Natural Gas as identified in US EPA Rule Part 98A Table C-3 (US weighted average) for Amgen's facility in Cambridge, Massachusetts. Carbon data from indirect energy sources prior to 2011 were calculated using emission factors from US EPA eGRID2007 Version 1.1 for US facilities.

Other Carbon

- (h) The Other Carbon category contains additional Scope 1 and Scope 3 carbon emissions that are tracked. Carbon emissions from our executive air fleet are calculated using emission factors from the Greenhouse Gas Protocol Cross-Sector Tools-Transport-Fuel-Use (August 2012). Carbon emissions from our US sales fleet are calculated using emission factors from the GHG Protocol Emission Factors for Petrol passenger cars (volume) (GHG Protocol) = 8.81 kg/gal. Fuel use and mileage data are collected at the pump for each vehicle. Carbon emissions from our commercial business travel are calculated by Amgen's travel provider using the Defra tool. Carbon emissions from Amgen's material transportation have been provided by the carrier using its own specific methods. Fugitive emissions from process equipment (e.g., refrigerant from refrigeration and HVAC equipment) are calculated using emission factors from the Greenhouse Gas Protocol Cross-Sector Tools-Transport-Fuel-Use (August 2012). Processes are in place to maintain chillers, coolers, and HVAC equipment to prevent unintended emissions.
- (i) Scope 3 carbon emissions are a consequence of the activities of the company but occur from sources not owned or controlled by the company. Scope 3 carbon emissions that are currently tracked include emissions from Amgen's commercial business travel (air and rail) and material transportation.
- (i) Commercial business travel was not tracked in 2007 or 2008. Material transportation was not tracked from 2007 to 2011. The accuracy of carbon emissions tracking from chillers, coolers, and HVAC improved in 2013 and will now be reported going forward.

Water

- (k) Immaterial discrepancy between values for total water fate and total water withdrawal is due to rounding and compilation of individual facility totals.

Waste

- (l) Recycling rate is the proportion of waste that is recycled, composted, and reused compared with the total volume of routine, nonhazardous and hazardous waste generated. Diversion from landfill is the proportion of waste that is incinerated (both for energy recovery and not), landfilled, and treated compared with the total routine, nonhazardous waste generated.
- (m) Treatment means the physical, thermal, chemical, or biological processes that change the characteristics of the waste in order to reduce its volume or hazardous nature, facilitate its handling, or enhance recovery.
- (n) Nonroutine waste constitutes waste generated outside the normal operations of our facilities and consists mainly of construction and demolition waste.

Fleet

- (o) Emissions and fuel use avoided are the result of improvements in fleet efficiency from years 2007 through 2012 based on a 2007 baseline, and 2013+ based on a 2012 baseline.

Compliance

- (p) Environmental notices of violation (NOVs) reported that resulted from agency inspections.



INDEPENDENT ASSURANCE STATEMENT

Introduction and objectives of work

Bureau Veritas North America, Inc. (BVNA) has been engaged by Amgen to conduct an independent assurance of selected environmental data included in Amgen's 2015 Environmental Sustainability Report.

This Assurance Statement applies to the related information included within the scope of work described below.

The data presented in Amgen's 2015 Environmental Sustainability Report is the sole responsibility of the management of Amgen. BVNA was not involved in the drafting of the Report. Our sole responsibility was to provide independent verification of the accuracy of selected information included in the Report.

Scope of work

Amgen requested BVNA to verify the accuracy of the following environmental data summarized in Amgen's Environmental Sustainability Report for the Calendar Year 2015 reporting period:

- Energy Use (Total, Direct and Indirect)
- Greenhouse Gas Emissions (Direct Scope 1 and Indirect Scope 2 location-based)
- Water Withdrawal and Fate
- Waste Quantities and Disposition

Excluded from the scope of our work is any verification of information relating to:

- Text or other written statements associated with Amgen's 2015 Environmental Sustainability Report
- Activities outside the defined verification period of Calendar Year 2015

Methodology

As part of its independent verification, BVNA undertook the following activities:

1. Interviews with relevant personnel of Amgen regarding data collection and reporting systems;
2. Review of Amgen's data and information systems and methodology for collection, aggregation, analysis and internal audit of information used to determine the environmental data;
3. Review of documentary evidence produced by Amgen;
4. Audit of Amgen's data traced back to the source for facilities located in Providence, Rhode Island and Juncos, Puerto Rico during site visits; and
5. Review of the centralized data, methods for consolidation of site data and site data available in the centralized data management system during a visit to Amgen's headquarters location in Thousand Oaks, California.

Our assurance work was conducted in accordance with Bureau Veritas procedures based on the International Standard on Assurance Engagements (ISAE) 3000 and ISO Standard 14064-3 Greenhouse Gases - Part 3: Specification with Guidance for the Validation and Verification of Greenhouse Gas Assertions. In accordance with our internal procedures for limited assurance, we use these as our reference standards.

Amgen



Page 2

The work was planned and carried out to provide data verification to a limited assurance level and we believe it provides an appropriate basis for our conclusions.

Our findings

On the basis of our methodology and the activities described above:

- Nothing has come to our attention to indicate that the reviewed information within the scope of our verification is not materially correct.
- Nothing has come to our attention to indicate that the reviewed information is not a fair representation of the actual environmental data for calendar year 2015.
- It is our opinion that Amgen has established appropriate systems for the collection, aggregation and analysis of quantitative data, including energy use, direct and indirect GHG emissions, water withdrawal and fate and waste quantities and disposition.
- A summary of data within the scope of assurance for 2015 is attached.

Statement of independence, impartiality and competence

BVNA is part of The Bureau Veritas Group, an independent professional services company that specializes in Quality, Health, Safety, Social and Environmental management with almost 180 years of history in providing independent assurance services, and an annual 2015 revenue of 4.9 Billion Euros.

No member of the verification team has a business relationship with Amgen, its Directors or Managers beyond that required of this assignment. We have conducted this verification independently, and there has been no conflict of interest.

BVNA has implemented a Code of Ethics across the business to maintain high ethical standards among staff in their day to day business activities.

Attestation:

Lisa S. Barnes, Lead Verifier
Practice Line Leader
Sustainability and Climate Change Services
Bureau Veritas North America, Inc.
Denver, Colorado

Trevor Donaghu, Project Reviewer
Technical Director
Climate Change Services
Bureau Veritas North America, Inc.

April 6, 2016



“As a biology-focused company, we have a deep appreciation for the natural environment. We continuously improve operations in a variety of ways to improve our environmental impact.”

— Robert A. Bradway, Chairman and CEO, Amgen

To view Amgen's full 2015 Environmental Sustainability Report, see environment.amgen.com. We welcome your feedback.

Forward-Looking Statements

This brochure contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including those related to our environmental sustainability program design; expected environmental sustainability goals, targets, plans, focus areas, savings or progress towards any of the same; current and future R&D, manufacturing, commercialization, infrastructure or other workplace-related processes, improvements or practices and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this brochure and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We are increasingly dependent on information technology systems, infrastructure and data security. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.



MEMBER OF

Dow Jones Sustainability Indices

In Collaboration with RobecoSAM 



Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com

©2016 Amgen Inc. All rights reserved.

Design by Saputo Design, Inc.

Printed on paper made with 100% post-consumer waste.

 Please recycle.